DexCom Inc (NASDAQ:DXCM) is facing renewed scrutiny after three people with diabetes reportedly died following issues with its G7 continuous glucose monitor, according to adverse event filings submitted to the Food and Drug Administration in September.DXCM is lagging behind market performance. Get the complete picture here.A recent investigation by Hunterbrook alleged that Dexcom "dropped the ball" in ensuring the accuracy and reliability of its G7 glucose monitoring device.Some patients reportedly experien ...